Tag:

Pronova BioPharma

Latest Headlines

Latest Headlines

BASF makes its 'final offer' to Pronova shareholders

Recalcitrant Pronova BioPharma shareholders need to face reality, BASF says. The German chemicals giant has raised its bid for the fish-oil drugs maker, but only slightly--to €684 million ($910 million) from €644 million ($856.8 million).

Fish-oil drugmaker Pronova sells to Germany's BASF for $844M

BASF, the German chemicals giant, plans to gobble up Norway's Pronova BioPharma, maker of the active ingredient in GlaxoSmithKline's blockbuster omega-3 drug Lovaza, in a cash buyout valued at NOK 4,845 million or $844 million.

BASF to snap up fish oil drugmaker Pronova BioPharma in $844M buyout

This might not be the big fish-oil drug acquisition industry watchers were anticipating. BASF, the German chemicals giant, plans to gobble up Norway's Pronova BioPharma, maker of the active ingredient in GlaxoSmithKline's blockbuster omega-3 drug Lovaza, in a cash buyout valued at NOK 4,845 million or $844 million.

GSK partner holds off generic rival for Lovaza

GlaxoSmithKline and its Lovaza partner may escape generic competition on the drug until 2015. Pronova BioPharma, which makes the fish-oil-derived treatment, inked a deal with Apotex that allows the